Evidence map›Paper›PMID 41114123›Full record

ReviewAutophagy reports2025

Targeting macroautophagy to combat neurodegenerative disease: strategies and considerations.

Glenn M Duncan, Ai Yamamoto

Abstract readReview
In one paragraph

Review in Autophagy reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Glenn M DuncanDoctoral Program in Neurobiology and Behavior, Columbia University, New York, NY.
Ai YamamotoDepartment of Neurology, New York, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Upon demonstration that basal macroautophagy plays an essential role in maintaining protein homeostasis in the mammalian CNS, there has been excitement around modulating this form of autophagy as a therapeutic strategy to combat neurodegenerative disease. Nonetheless, the initial genetic studies that spawned this excitement did little to reveal the complex physiology of autophagy regulation in neural cells, or the predicament of compartment-specific events upon which these cells rely. Pursuit of therapeutic strategies further highlighted how this intricacy extends across the different organs of the body, raising question as to how we may harness the power of macroautophagy for good while minimizing the bad. Fortunately, since these early studies, the field has made significant gains toward understanding the molecular, cellular and physiological basis of macroautophagy. Together with technological advances, they have refueled the exploration into how this powerful pathway may provide the much-needed therapeutic advances for these yet untreatable diseases. In this review, we will contextualize the insights gained over the last decade with the traditional and novel strategies that have been explored to combat disease-associated events such as abnormal protein accumulation. In addition, we will discuss key considerations and strategies that can influence how a therapeutic approach might be designed.

Indexed as

Autophagyneurodegenerationselective autophagytherapeutics

Identifiers

PMID41114123
PMCPMC12533962

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.